FDA allowsdruster of cervical cancer: experts
The U.S.
Food and Drug Administration on Wednesday granted emergency use authorization (EUA) to AstraZeneca Plc’s cervical cancer vaccine candidate AG-CNF12b-01 in the company’s advanced development pipeline and confirmed results in clinical trials.
The article corrects the name of the study performed in conjunction with AstraZeneca’s UNILROM center in Oxford, not the Lillehammer unit.
The clearance in the EUA review of AG-CNF12b-01 “is an important milestone and reinforces the ability of our regulatory system to prioritize product candidates for development at the highest public health, societal, and ethical levels”, FDA Commissioner Scott Gottlieb said in its statement.
The two trials are already in late-stage studies phase 3 for their respective indications.